Biocon reported 3Q26 results that missed analyst estimates due to higher SG&A expenses, though the Generics division outperformed. Analysts remain Neutral, focusing on upcoming biosimilar launches in FY27 and interest savings from recent debt reduction.
Key Takeaways
- 1.Biocon's 3Q26 earnings were below expectations, with an EBITDA margin of 19.7% missing the GS estimate of 21.2% due to higher SG&A costs.
- 2.The Generics segment showed strong growth (+24% yoy) driven by European launches like Liraglutide and expansion in oral solids.
- 3.Biosimilar revenue growth slowed to 9% yoy as the company focused on manufacturing upgrades ahead of major FY27 launches.
Table of Contents
- 3Q26 Summary
- Generics Performance
- GS Forecast
- Financial Statements
- Steady Biosimilar performance
- Balance sheet updates
- Research services reiterates FY26 guidance
- Valuation
- Key risks
- Disclosure Appendix
Document Preview
Access the Full Report
Get unlimited access to institutional research reports with a 14-day free trial.
Authors
Shyam SrinivasanKaran Vora
Securities
Syngene InternationalBION.BO
Themes
Biosimilar Launch PipelineDeleveraging and Interest ReductionGLP-1 Expansion
Regions
Asia PacificIndia